Core Insights - The company, Green Bamboo Bio-B (02480), announced positive immunogenicity and safety data from a head-to-head comparison trial of its core product LZ901 against the HZ/su vaccine (Shingrix®) in adults aged 50 and above [1] Group 1: Trial Details - The study was a randomized, active-controlled, and non-inferiority trial that recruited 301 healthy adults aged 50 and above, with at least 291 receiving two doses of either LZ901 or HZ/su vaccine [1] - Results indicated that LZ901 induced superior cellular immunogenicity and demonstrated better safety compared to the HZ/su vaccine in the target age group [1] Group 2: Product Information - LZ901 is a recombinant shingles vaccine developed by the company, aimed at preventing shingles and related complications, including postherpetic neuralgia, in adults aged 40 and above [1] - As of the announcement date, the biological product license application for LZ901 has been accepted by the National Medical Products Administration of the People's Republic of China and is currently under review [1]
绿竹生物-B(02480)：LZ901头对头比较研究的积极临床数据